The associated clinical data of patients with early RA were also evaluated.

Conclusion: Anti-MCV is a novel diagnostic marker for early RA.

This underlines the prognostic importance of disability in early RA.

Sixty patients with early RA, and 80 with seronegative spondyloarthropathy were included as control groups.

Conclusion: For early RA patients, the SvH seems preferable if analyses on individual level are included.

In patients with early RA, TNF-a-antagonists show a more rapid onset of anti-inflammatory effects than Methotrexate.

We evaluated the diagnostic value of anti-MCV in a large cohort of Chinese patients with early RA.

It may be more useful if the anti-CCP2 assay is performed concomitantly to diagnose patients with early RA.

A control group consisted of early RA patients treated with a combination of methotrexate (MTX) and methylprednisolone.

It was mainly designed to identify prognostic factors of joint destruction, disability and remission in patients with early RA.

Conclusions: Beyond plasma lipids, increased levels of small, dense LDL seems to be common in drug-naïve patients with early RA.

Methods: We evaluated 524 patients with RA enrolled in the Combination Anti-Rheumatic Drugs in Early RA (CARDERA) trials.

We review data from randomized clinical trials regarding the impact of these treatment strategies as the initial therapy in early RA.

Conclusion: A short-term decrease in circulating visfatin may represent an independent predictor of long-term disease activity improvement in patients with early RA.

Study design and setting: Films of 51 patients representing the spectrum of early RA were read by two raters for each method.

Using multivariate analysis, only latex, RF test and AKA or APF had an independent and statistically significant diagnostic value for early RA.